{"id":"NCT03323385","sponsor":"Baudax Bio","briefTitle":"Evaluation of Preoperative N1539 in Colorectal Surgery","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety and Efficacy of Preoperative N1539 In Colorectal Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-24","primaryCompletion":"2018-09-26","completion":"2018-09-26","firstPosted":"2017-10-27","resultsPosted":"2023-06-18","lastUpdate":"2023-06-18"},"enrollment":57,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain, Postoperative"],"interventions":[{"type":"DRUG","name":"N1539","otherNames":["Intravenous meloxicam"]},{"type":"DRUG","name":"Placebo","otherNames":["Intravenous placebo"]}],"arms":[{"label":"N1539 30 mg","type":"EXPERIMENTAL"},{"label":"IV Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the safety and tolerability of preoperative dosing of N1539 30 mg in subjects undergoing colorectal surgery, including clinical laboratory tests, wound healing evaluation, incidence of anastomotic leaks, and incidence of Adverse Events (AEs) and Serious AEs (SAEs).","primaryOutcome":{"measure":"Evaluation of Safety and Tolerability - Number of Subjects With an AE","timeFrame":"Up to 30 days","effectByArm":[{"arm":"N1539 30 mg","deltaMin":23,"sd":null},{"arm":"IV Placebo","deltaMin":26,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["33094682"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":27},"commonTop":["Nausea","Vomiting","Ileus","Constipation","Urinary retention"]}}